JP2018529661A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018529661A5 JP2018529661A5 JP2018511144A JP2018511144A JP2018529661A5 JP 2018529661 A5 JP2018529661 A5 JP 2018529661A5 JP 2018511144 A JP2018511144 A JP 2018511144A JP 2018511144 A JP2018511144 A JP 2018511144A JP 2018529661 A5 JP2018529661 A5 JP 2018529661A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- light chain
- heavy chain
- sequence
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021134828A JP2021185169A (ja) | 2015-09-01 | 2021-08-20 | ループス腎炎の処置のための抗ｃｄ４０抗体の使用 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562212810P | 2015-09-01 | 2015-09-01 | |
| US62/212,810 | 2015-09-01 | ||
| US201562257336P | 2015-11-19 | 2015-11-19 | |
| US62/257,336 | 2015-11-19 | ||
| US201662287587P | 2016-01-27 | 2016-01-27 | |
| US62/287,587 | 2016-01-27 | ||
| PCT/US2016/049558 WO2017040566A1 (en) | 2015-09-01 | 2016-08-31 | Use of anti-cd40 antibodies for treatment of lupus nephritis |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021134828A Division JP2021185169A (ja) | 2015-09-01 | 2021-08-20 | ループス腎炎の処置のための抗ｃｄ４０抗体の使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018529661A JP2018529661A (ja) | 2018-10-11 |
| JP2018529661A5 true JP2018529661A5 (enExample) | 2019-10-10 |
Family
ID=56896810
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018511144A Pending JP2018529661A (ja) | 2015-09-01 | 2016-08-31 | ループス腎炎の処置のための抗ｃｄ４０抗体の使用 |
| JP2021134828A Pending JP2021185169A (ja) | 2015-09-01 | 2021-08-20 | ループス腎炎の処置のための抗ｃｄ４０抗体の使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021134828A Pending JP2021185169A (ja) | 2015-09-01 | 2021-08-20 | ループス腎炎の処置のための抗ｃｄ４０抗体の使用 |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US20170058038A1 (enExample) |
| EP (1) | EP3344655B1 (enExample) |
| JP (2) | JP2018529661A (enExample) |
| KR (1) | KR20180039172A (enExample) |
| CN (1) | CN107922501A (enExample) |
| AU (1) | AU2016317028B2 (enExample) |
| BR (1) | BR112018001907A2 (enExample) |
| CA (1) | CA2993996A1 (enExample) |
| CL (1) | CL2018000317A1 (enExample) |
| DK (1) | DK3344655T5 (enExample) |
| ES (1) | ES2969968T3 (enExample) |
| HU (1) | HUE063528T2 (enExample) |
| MX (1) | MX390653B (enExample) |
| PH (1) | PH12018500445B1 (enExample) |
| PL (1) | PL3344655T3 (enExample) |
| WO (1) | WO2017040566A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI640536B (zh) | 2016-06-20 | 2018-11-11 | 克馬伯有限公司 | 抗體 |
| EP3824906A1 (en) | 2016-12-21 | 2021-05-26 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| MX2019013132A (es) * | 2017-05-25 | 2020-01-27 | Bristol Myers Squibb Co | Anticuerpos que comprenden regiones constantes pesadas modificadas. |
| JP7504808B2 (ja) * | 2018-06-29 | 2024-06-24 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 自己免疫疾患の処置における使用のための抗ｃｄ４０抗体 |
| WO2020108621A1 (zh) * | 2018-11-30 | 2020-06-04 | 江苏恒瑞医药股份有限公司 | 一种cd40抗体药物组合物及其用途 |
| SI4284512T1 (sl) | 2021-01-28 | 2025-06-30 | Regeneron Pharmaceuticals, Inc. | Sestavki in postopki za zdravljenje sindroma sproščanja citokinov |
| US20250276092A1 (en) | 2024-03-01 | 2025-09-04 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response |
| WO2025184603A2 (en) | 2024-03-01 | 2025-09-04 | Regeneron Pharmaceuticals, Inc. | The use of cd40 inhibitors for inhibiting an immune response and enabling immunogen administration and re-administration |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| EP0206448B1 (en) | 1985-06-19 | 1990-11-14 | Ajinomoto Co., Inc. | Hemoglobin combined with a poly(alkylene oxide) |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| EP0940468A1 (en) | 1991-06-14 | 1999-09-08 | Genentech, Inc. | Humanized antibody variable domain |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| DK0656789T3 (da) | 1992-08-21 | 1998-08-24 | Genentech Inc | Fremgangsmåde til behandling af en LFA-1-medieretforstyrrelse. |
| US6037454A (en) | 1996-11-27 | 2000-03-14 | Genentech, Inc. | Humanized anti-CD11a antibodies |
| US20030059427A1 (en) * | 2000-04-28 | 2003-03-27 | Force Walker R. | Isolation and characterization of highly active anti-CD40 antibody |
| US8277810B2 (en) * | 2003-11-04 | 2012-10-02 | Novartis Vaccines & Diagnostics, Inc. | Antagonist anti-CD40 antibodies |
| KR20070026522A (ko) * | 2004-04-27 | 2007-03-08 | 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 | 길항제 항-ｃｄ40 모노클론 항체 및 이들의 사용 방법 |
| CA2609269C (en) * | 2005-05-26 | 2014-08-05 | Seattle Genetics, Inc. | Humanized anti-cd40 antibodies and their methods of use |
| US8945564B2 (en) * | 2006-04-21 | 2015-02-03 | Novartis Ag | Antagonist anti-CD40 antibody pharmaceutical compositions |
| PT3178851T (pt) | 2010-03-31 | 2020-07-17 | Boehringer Ingelheim Int | Anticorpos anti-cd40 |
| WO2012149356A2 (en) * | 2011-04-29 | 2012-11-01 | Apexigen, Inc. | Anti-cd40 antibodies and methods of use |
| US20140004131A1 (en) * | 2012-05-04 | 2014-01-02 | Novartis Ag | Antibody formulation |
-
2016
- 2016-08-31 CA CA2993996A patent/CA2993996A1/en active Pending
- 2016-08-31 US US15/252,308 patent/US20170058038A1/en not_active Abandoned
- 2016-08-31 WO PCT/US2016/049558 patent/WO2017040566A1/en not_active Ceased
- 2016-08-31 PH PH1/2018/500445A patent/PH12018500445B1/en unknown
- 2016-08-31 AU AU2016317028A patent/AU2016317028B2/en not_active Ceased
- 2016-08-31 HU HUE16763663A patent/HUE063528T2/hu unknown
- 2016-08-31 DK DK16763663.8T patent/DK3344655T5/da active
- 2016-08-31 JP JP2018511144A patent/JP2018529661A/ja active Pending
- 2016-08-31 ES ES16763663T patent/ES2969968T3/es active Active
- 2016-08-31 BR BR112018001907A patent/BR112018001907A2/pt not_active Application Discontinuation
- 2016-08-31 EP EP16763663.8A patent/EP3344655B1/en active Active
- 2016-08-31 PL PL16763663.8T patent/PL3344655T3/pl unknown
- 2016-08-31 CN CN201680050230.6A patent/CN107922501A/zh active Pending
- 2016-08-31 MX MX2018002447A patent/MX390653B/es unknown
- 2016-08-31 KR KR1020187009176A patent/KR20180039172A/ko not_active Ceased
-
2018
- 2018-02-05 CL CL2018000317A patent/CL2018000317A1/es unknown
- 2018-07-18 US US16/038,536 patent/US20190177420A1/en not_active Abandoned
-
2021
- 2021-08-20 JP JP2021134828A patent/JP2021185169A/ja active Pending
-
2022
- 2022-10-07 US US17/962,099 patent/US20230265203A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018529661A5 (enExample) | ||
| JP2020062036A5 (enExample) | ||
| JP2019505527A5 (enExample) | ||
| JP2019535763A5 (enExample) | ||
| JP2018500014A5 (enExample) | ||
| JP2018527919A5 (enExample) | ||
| RU2015143886A (ru) | Антитела к тау и способы применения | |
| JP2015514110A5 (enExample) | ||
| JP2020502271A5 (enExample) | ||
| JP2017529838A5 (enExample) | ||
| JP2019523295A5 (enExample) | ||
| JP2016507470A5 (enExample) | ||
| JP2012525128A5 (enExample) | ||
| JP2013538553A5 (enExample) | ||
| JP2018505177A5 (enExample) | ||
| JP2014158469A5 (enExample) | ||
| RU2016137256A (ru) | АНТИТЕЛА К ФАКТОРУ КОМПЛЕМЕНТА Bb | |
| JP2015503909A5 (enExample) | ||
| JP2015520758A5 (enExample) | ||
| JP2017507652A5 (enExample) | ||
| RU2016137110A (ru) | Антитела к компоненту комплемента с5 | |
| EA202091590A1 (ru) | Антитела против pd-l1 и варианты их применения | |
| JP2018506277A5 (enExample) | ||
| RU2018129874A (ru) | Антитела против фактора свертывания xi | |
| JP2016094424A5 (enExample) |